>  Actos



ctos (pioglitazone) is a drug developed by Takeda Pharmaceuticals for the treatment of type-2 diabetes, a condition where the body does not efficiently produce insulin and cannot effectively regulate sugar in the blood. When the drug was first made available to the public in 1999, it was well received and quickly became popular among patients and doctors. By 2009, sales of Actos rose to $3.4 billion.

The U.S. Food and Drug Administration (FDA) issued a warning in September of 2010 about Actos and its link to bladder cancer after reviewing data from a ten-year study conducted by Takeda Pharmaceutical Company, the drug manufacturer. When results of another study on Actos by the French government also found a link between Actos and bladder cancer in June of 2011, regulators in France and Germany issued an Actos recall, pulling the drug from the market. The FDA mandated that information about the increased risk of bladder be added to the label of the drug and advised that Actos not be prescribed to people with bladder cancer or a history of bladder cancer.

Many Actos users who developed bladder cancer have filed lawsuits against Takeda since the connection between the drug and bladder cancer came to light. Timothy Litzenburg was a member of the trial team for six of the seven Actos trials in the mass tort litigation. Mr. Litzenburg has helped secure several million and multi-million dollar verdicts on behalf of Actos bladder cancer victims. Our firm is uniquely positioned to fight for justice on your behalf.

If you began taking Actos prior to June 2011 for the treatment of type 2 diabetes and you were later diagnosed with bladder cancer, contact us at 804.466.4412. You may be eligible for compensation.

Need help with legal issues?

None of the information on this site is intended as legal advice. For specific advice pertaining to your particular situation, please consult an attorney. Nothing contained on the website is or should be construed as legal advice, and your use of this website creates no attorney-client relationship with Kincheloe, Litzenburg & Pendleton, PLLC.  If you choose to contact us through our website about legal services, please understand that it will not constitute an agreement to provide legal services to you nor will such action establish an attorney-client relationship.

Kincheloe, Litzenburg & Pendleton, PLLC is committed to protecting your online privacy. We collect only the information submitted by you directly via our contact form and use that information only to respond to your inquiries and to send you information about the firm and its services. We will not share any information with third-parties without your express permission.

To the extent required by the rules of the Virginia State Bar or the rules of any other state, Kincheloe, Litzenburg & Pendleton, PLLC designates Daniel Kincheloe as the attorney responsible for the website.